PBAC's latest decision on Erenumab: Recommended with restriction (2024). Considered for Prophylaxis of chronic migraine in adults who have experienced an inadequate response, intolerance or a contraindication to at least 3 prophylactic migraine medications.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2018
Submissions
3
2018 → 2024
Eligible population
Adults with chronic migraine (≥15 headache days per month with ≥8 migraine days) who have experienced inadequate response, intolerance or contraindication to at least 3 prophylactic migraine medications.
Therapy area
Neurology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Reduction in monthly migraine days
Pivotal trial size
667 patients
Key trials
Study 295, DRAGON, Study 609, REGAIN, CONQUER, FOCUS, HALO-CM, NCT03303079, DELIVER, PROMISE-2, Study 005
Comparator
galcanezumab, fremanezumab, eptinezumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation approach; no ICER calculated. Document states erenumab was non-inferior in effectiveness and safety compared to comparators.
Submission history
Jul 2018: Recommended with restriction · Authority Required
Mar 2019: Deferred · Authority Required
Nov 2024: Recommended with restriction · Authority Required